Find in Library

The adenosine A_2A receptor (A_2AR) is regarded as a particularly appropriate target for non-dopaminergic treatment of Parkinson’s disease (PD). An increased A_2AR availability has been found in the human striatum at early stages of PD and in patients with PD and dyskinesias. The aim of this small animal positron emission tomography/magnetic resonance (PET/MR) imaging study was to investigate whether rotenone-treated mice reflect the aspect of striatal A_2AR upregulation in PD. For that purpose, we selected the known A_2AR-specific radiotracer [¹⁸F]<b>FESCH</b> and developed a simplified two-step one-pot radiosynthesis. PET images showed a high uptake of [¹⁸F]<b>FESCH</b> in the mouse striatum. Concomitantly, metabolism studies with [¹⁸F]<b>FESCH</b> revealed the presence of a brain-penetrant radiometabolite. In rotenone-treated mice, a slightly higher striatal A_2AR binding of [¹⁸F]<b>FESCH</b> was found. Nonetheless, the correlation between the increased A_2AR levels within the proposed PD animal model remains to be further investigated.